

HTx

Next Generation Health Technology Assessment

EU Horizon 2020 Project

Dalia Dawoud, PhD

Scientific Adviser

Science Policy and Research

National Institute for Health and Care Excellence (NICE)

United Kingdom



@drddawoud



<https://www.linkedin.com/in/dalia-dawoud-8b2478159/>



dalia.dawoud@nice.org.uk



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.

Background

- **Aligning** health technology assessment (HTA) and clinical practice guidelines (CPG) recommendations is an **essential**, but **challenging**, task
- **Consistent** and **coordinated** messages required now more than ever.
- **Processes**, as well as **outputs**, need to be harmonised
- **It takes two to tango!**



Background

- **Priority** area for **NICE** as an organisation that produces both **CPGs** and **TAs**
- The **range and volume of our guidance** creates internal challenges in keeping it **up to date**, **aligning our work programmes** and data management, as well as the **efficient analysis and presentation of complex information**



Background



NICE Connect

Reviewing how we produce and present
guidance.

Advice and guidance integrated in a care
pathway format – the ‘front door’



<https://www.nice.org.uk/about/who-we-are/nice-connect>

CHTE2020

Technology Appraisal Methods Review

Review of NICE methods for both technology appraisals
(TAs) and highly specialised technologies (HSTs),
including a review of the process of guidance
production for HST.



<https://tinyurl.com/y88sejh2>



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.

Science Policy and Research

HTx: Next Generation Health Technology Assessment

Horizon 2020 project funded by the European Union (2019-2023)



Utrecht University (UU)
Netherlands - Project Coordinator



University of Maastricht (UM)
Netherlands



EURORDIS Rare Diseases Europe (EURORDIS)
France



University of Copenhagen (UoC)
Denmark



University of Oulu (UoO)
Finland



University of York (UoY)
UK



Medical University of Sofia (MUS)
Bulgaria



University of Bern (UBER)
Switzerland



Universidad Politécnica de Madrid
Spain



European Organisation for Research and Treatment of Cancer (EORTC)
Belgium



Dental and Pharmaceutical Benefits Agency (TLV)
Sweden



National Health Care Institute (ZIN)
Netherlands

NICE

National Institute of Health and Care Excellence (NICE)
UK

syreon
Research Institute

Syreon Research Institute (SRI)
Hungary

SYNAPSE

Synapse research management (SYNAPSE)
Spain



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.

HTx 2nd General Assembly
Bern, 6-7 February 2020

Objectives


- To **create a framework for next generation HTA** that supports **patient-centered, societally oriented, real-time decision-making** for **integrated healthcare** throughout **Europe**.
- To **facilitate the development of methodologies** to deliver more **customized information** on the **effectiveness** and **cost-effectiveness** of **complex** and **personalised combinations** of health technologies.
- To provide methods to support **personalised treatment advice** that will be shared with **patients** and **their physicians**



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.



Structure



Objectives- WP4

Implementation into systems and processes



- International consensus building on the HTx methods. That will include **building consensus** between HTA organisations in Europe and between HTA organisations, **regulators** and **guideline developing organisations**.
- To increase patient-centricity in decision-making.
- To support development of flexible funding and reimbursement models for complex health technologies. This also includes assessment of the transferability of these models throughout Europe



Methodology

1. Descriptive study

- a. HTA organisations
- b. CPG developers

2. Document review



1. Descriptive study

- Aim
 - to explore the currently existing synergies after marketing approval, between HTA agencies and clinical guideline development (both formal in person collaborations and utilisation of documents developed by both parties).
 - To identify critical aspects where further improvement in synergies is needed.
- Methods
 - Online questionnaire
 - Face-to-face (virtual?) workshop



Questionnaire development and administration



Utrecht University (UU)
Netherlands – Project
Coordinator



Dental and
Pharmaceutical Benefits
Agency (TLV)
Sweden



University of Copenhagen
(UoC)
Denmark



NICE National Institute for
Health and Care Excellence

National Health Care
Institute (ZIN)
Netherlands

Background

Literature

Experts

Conceptualisation

Collaboration

Regular TCs

Format

Online

Validity

Expert
Readability
Pilot testing

Reliability

Pilot testing



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.

Questionnaire development and administration



**Experience in HTx
case study areas**

**Formal and informal
collaboration with
CPG developers**

**Benefits and
Challenges of closer
working**

Information needs



Questionnaire development and administration

Dissemination	Communication	Data analysis
28 East + West EU countries	Announcements	Ongoing
EUnetHTA partners	Reminders	LimeSurvey tools



**21 HTA organisations completed
the questionnaire**



2. Document Review

- Aim
 - To investigate whether **recommendations** from **6 European HTA organisations** in published documents, are in line with the recommendations in **CPG documents**.
- **Multiple sclerosis** will be used as a case study for the analysis



Next Steps

- **CPG developers** to receive the questionnaire later this year.
 - Please, take time to complete it
- Joint **face-to-face/virtual workshop** for HTA organisations and CPG developers



Acknowledgements

- Milou Hogervorst
- Wim Goettsch
- Diana Delonij
- Ayla Lokhorst
- Emily Leckenby
- Páll Jónsson
- HTx WP4 Team
- HTx Consortium Partners



Utrecht University (UU)
Netherlands – Project
Coordinator



**National Health Care
Institute (ZIN)**
Netherlands

NICE National Institute for
Health and Care Excellence



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.

Acknowledgments

NICE National Institute for
Health and Care Excellence

Thank You!



Next Generation Health Technology Assessment

Website: www.htx-h2020.eu

E-mail: info@htx-h2020.eu


 [@htx_h2020](https://twitter.com/htx_h2020)

 <https://www.linkedin.com/company/htx-h2020/>



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.

Concept



© The HTx Consortium 2019-2023. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 825162.